LncRNA DYNLRB2-AS1 promotes gemcitabine resistance of nasopharyngeal carcinoma by inhibiting the ubiquitination degradation of DHX9 protein
Drug Resistance Updates · 2024-09 · 76 · 101111
DOI: 10.1016/j.drup.2024.101111 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Resistance Updates, 2024-09. Verfasst von Kai-Lin Chen und 15 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Cli…. Hauptthemen laut MEDLINE: DEAD-box RNA Helicases, Deoxycytidine, Gemcitabine, Nasopharyngeal Carcinoma. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 61 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Gemcitabine (GEM) based induction chemotherapy is a standard treatment for locoregionally advanced nasopharyngeal carcinoma (NPC). However, approximately 15 % of patients are still resistant to GEM-containing chemotherapy, which leads to treatment failure. Nevertheless, the underlying mechanisms of GEM resistance remain poorly understood. Herein, based on a microarray analysis, we identified 221 dysregulated lncRNAs, of which, DYNLRB2-AS1 was one of the most upregulated lncRNAs in GEM-resistance NPC cell lines. DYNLRB2-AS1 was shown to function as contain an oncogenic lncRNA that promoted NPC GEM resistance, cell proliferation, but inhibited cell apoptosis. Mechanistically, DYNLRB2-AS1 could directly bind to the DHX9 protein and prevent its interaction with the E3 ubiquitin ligase PRPF19, and thus blocking PRPF19-mediated DHX9 degradation, which ultimately facilitated the repair of DNA damage in the presence of GEM. Clinically, higher DYNLRB2-AS1 expression indicated an unfavourable overall survival of NPC patients who received induction chemotherapy. Overall, this study identified the oncogenic lncRNA DYNLRB2-AS1 as an independent prognostic biomarker for patients with locally advanced NPC and as a potential therapeutic target for overcoming GEM chemoresistance in NPC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center…
- Department of Head and Neck Oncology, the Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai 519000, China.
Förderung
- National Natural Science Foundation of China
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Chen, K. L., Huang, S. W., Yao, J. J., He, S. W., Gong, S., Tan, X. R., Liang, Y. L., Li, J. Y., Huang, S. Y., Li, Y. Q., Zhao, Y., Qiao, H., Xu, S., Zang, S., Ma, J., & Liu, N. (2024). LncRNA DYNLRB2-AS1 promotes gemcitabine resistance of nasopharyngeal carcinoma by inhibiting the ubiquitination degradation of DHX9 protein. Drug Resistance Updates, 76, 101111. https://doi.org/10.1016/j.drup.2024.101111
Vancouver
Chen KL, Huang SW, Yao JJ, He SW, Gong S, Tan XR, et al. LncRNA DYNLRB2-AS1 promotes gemcitabine resistance of nasopharyngeal carcinoma by inhibiting the ubiquitination degradation of DHX9 protein. Drug Resistance Updates. 2024;76:101111. doi:10.1016/j.drup.2024.101111
BibTeX
@article{Chen2024,
author = {Chen, Kai-Lin and Huang, Sai-Wei and Yao, Ji-Jin and He, Shi-Wei and Gong, Sha and Tan, Xi-Rong and Liang, Ye-Lin and Li, Jun-Yan and Huang, Sheng-Yan and Li, Ying-Qin and Zhao, Yin and Qiao, Han and Xu, Sha and Zang, Shengbing and Ma, Jun and Liu, Na},
title = {LncRNA DYNLRB2-AS1 promotes gemcitabine resistance of nasopharyngeal carcinoma by inhibiting the ubiquitination degradation of DHX9 protein},
journal = {Drug Resistance Updates},
year = {2024},
volume = {76},
pages = {101111},
doi = {10.1016/j.drup.2024.101111}
}
EUVIMED